FibroGen Competitors

FibroGen (NASDAQ:FGEN) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and CureVac, as reported by MarketBeat.com.

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. CureVac has a consensus target price of $58.3333, suggesting a potential downside of 40.92%. Given FibroGen's stronger consensus rating and higher probable upside, equities analysts plainly believe FibroGen is more favorable than CureVac.

Profitability

This table compares FibroGen and CureVac's net margins, return on equity and return on assets.

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 4.3% of CureVac shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares FibroGen and CureVac's top-line revenue, earnings per share (EPS) and valuation.

CureVac has lower revenue, but higher earnings than FibroGen.

Summary

FibroGen beats CureVac on 6 of the 9 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and Horizon Therapeutics Public, as reported by MarketBeat.com.

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. Horizon Therapeutics Public has a consensus target price of $93.6667, suggesting a potential upside of 24.94%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, analysts plainly believe Horizon Therapeutics Public is more favorable than FibroGen.

Profitability

This table compares FibroGen and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.

Valuation & Earnings

This table compares FibroGen and Horizon Therapeutics Public's top-line revenue, earnings per share (EPS) and valuation.

Horizon Therapeutics Public has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Summary

Horizon Therapeutics Public beats FibroGen on 12 of the 14 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and BioMarin Pharmaceutical, as reported by MarketBeat.com.

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. BioMarin Pharmaceutical has a consensus target price of $116.50, suggesting a potential upside of 35.61%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than FibroGen.

Profitability

This table compares FibroGen and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 97.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Valuation & Earnings

This table compares FibroGen and BioMarin Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

BioMarin Pharmaceutical has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

BioMarin Pharmaceutical beats FibroGen on 11 of the 14 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and Elanco Animal Health, as reported by MarketBeat.com.

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. Elanco Animal Health has a consensus target price of $29.2778, suggesting a potential downside of 3.53%. Given FibroGen's stronger consensus rating and higher probable upside, equities analysts plainly believe FibroGen is more favorable than Elanco Animal Health.

Profitability

This table compares FibroGen and Elanco Animal Health's net margins, return on equity and return on assets.

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Comparatively, 0.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Valuation & Earnings

This table compares FibroGen and Elanco Animal Health's top-line revenue, earnings per share (EPS) and valuation.

Elanco Animal Health has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Elanco Animal Health beats FibroGen on 8 of the 14 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and Teva Pharmaceutical Industries, as reported by MarketBeat.com.

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. Teva Pharmaceutical Industries has a consensus target price of $12.2857, suggesting a potential downside of 0.28%. Given FibroGen's stronger consensus rating and higher probable upside, equities analysts plainly believe FibroGen is more favorable than Teva Pharmaceutical Industries.

Profitability

This table compares FibroGen and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

Valuation & Earnings

This table compares FibroGen and Teva Pharmaceutical Industries' top-line revenue, earnings per share (EPS) and valuation.

FibroGen has higher earnings, but lower revenue than Teva Pharmaceutical Industries. FibroGen is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

FibroGen (NASDAQ:FGEN) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Risk and Volatility

FibroGen has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Profitability

This table compares FibroGen and Grifols' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares FibroGen and Grifols' top-line revenue, earnings per share (EPS) and valuation.

Grifols has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 3.4% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for FibroGen and Grifols, as reported by MarketBeat.com.

FibroGen presently has a consensus target price of $60.00, suggesting a potential upside of 22.47%. Given FibroGen's higher probable upside, equities analysts plainly believe FibroGen is more favorable than Grifols.

Summary

Grifols beats FibroGen on 8 of the 13 factors compared between the two stocks.